1. Home
  2. MNMD vs FPF Comparison

MNMD vs FPF Comparison

Compare MNMD & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$13.44

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

FPF

First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

HOLD

Current Price

$18.78

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNMD
FPF
Founded
2019
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MNMD
FPF
Price
$13.44
$18.78
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$30.33
N/A
AVG Volume (30 Days)
2.0M
186.7K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
8.08%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$13.91
52 Week High
$14.43
$18.09

Technical Indicators

Market Signals
Indicator
MNMD
FPF
Relative Strength Index (RSI) 58.52 62.51
Support Level $12.70 $18.53
Resistance Level $14.28 $18.63
Average True Range (ATR) 0.70 0.12
MACD 0.10 0.04
Stochastic Oscillator 62.28 97.44

Price Performance

Historical Comparison
MNMD
FPF

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.

Share on Social Networks: